LYPD5 Inhibitors
LYPD5 Inhibitors encompass a variety of chemical compounds that interact with specific cellular pathways and processes to indirectly inhibit the functional activity of the protein LYPD5. These chemicals exert their effects through different mechanisms, such as altering membrane fluidity and signaling, inhibiting key kinases, or modulating ion channels, which can all lead to a decrease in LYPD5 activity. For instance, compounds like Palmitoyl-DL-carnitine and Cholesterol, by integrating into the cellular membrane, can modify membrane properties and subsequently impact the activity of membrane-associated proteins like LYPD5. Similarly, ion channel modulators such as Lidocaine can affect the membrane potential, leading to altered signaling cascades that can indirectly inhibit LYPD5.
Furthermore, several inhibitors target key enzymes and kinases that are involved in signaling pathways directly associated with LYPD5 function. Genistein, through its action as a tyrosine kinase inhibitor, and Bisindolylmaleimide I, as a PKC inhibitor, can disrupt the phosphorylation events that are crucial for the regulation of LYPD5 activity. LY294002, by inhibiting PI3K, impedes the PI3K/AKT signaling pathway, which could result in reduced LYPD5 activity. ML-7's inhibition of MLCK and Gö6976's targeting of specific protein kinases both lead to changes in phosphorylation dynamics, which are essential for the proper functioning of proteins like LYPD5.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Lidocaine acts as a sodium channel blocker. By altering ion flux, it indirectly affects signaling cascades that rely on changes in membrane potential, which could lead to reduced LYPD5 activity. | ||||||
Cholesterol | 57-88-5 | sc-202539C sc-202539E sc-202539A sc-202539B sc-202539D sc-202539 | 5 g 5 kg 100 g 250 g 1 kg 25 g | $27.00 $2809.00 $129.00 $210.00 $583.00 $88.00 | 11 | |
Cholesterol is integral to membrane structure and can modulate membrane fluidity. Alterations in membrane properties can affect membrane proteins and associated pathways, potentially inhibiting LYPD5 function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By inhibiting tyrosine kinases, it interferes with downstream signaling that may include pathways regulating LYPD5 activity, leading to its inhibition. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 is a calmodulin antagonist. By inhibiting calmodulin, it disrupts calcium signaling that can modulate the activity of proteins such as LYPD5 that may be regulated by calcium-dependent pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
This compound is a protein kinase C inhibitor. By inhibiting PKC, it disrupts signaling pathways that can lead to the inhibition of LYPD5 by affecting its phosphorylation state. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. It directly inhibits PI3K, which is crucial for the activation of the AKT signaling pathway, potentially leading to decreased LYPD5 activity due to less PI3K/AKT pathway activity. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK). Inhibition of MLCK can lead to alterations in the cytoskeletal dynamics, possibly leading to inhibited LYPD5 activity if LYPD5 is associated with such structures. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is a selective inhibitor for certain protein kinases including PKC. It can reduce LYPD5 activity by inhibiting related kinase activity that would ordinarily modulate LYPD5 activity through phosphorylation. | ||||||
PD 168393 | 194423-15-9 | sc-222138 | 1 mg | $162.00 | 4 | |
PD168393 is an irreversible inhibitor of EGFR tyrosine kinase. By blocking EGFR, it reduces downstream signaling that can modulate proteins such as LYPD5, leading to decreased activity. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 is a non-competitive inhibitor of neutral sphingomyelinase. By inhibiting this enzyme, it affects the ceramide signaling pathways, which may influence LYPD5 activity indirectly. | ||||||